Impact of Caregiver Beliefs on Adherence to Antipsychotic Medications in Patients With Schizophrenia (CroyAid-SCZ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03471013|
Recruitment Status : Recruiting
First Posted : March 20, 2018
Last Update Posted : February 4, 2019
Only one third of patients with schizophrenia are observant to their treatment knowing that the lack of adherence to treatment is one of the most important predictors of relapse.
Recent work shows that the erroneous or negative beliefs of patients with schizophrenia regarding antipsychotic treatment are associated with poor compliance.
The hypothesis is that negative beliefs about the antipsychotic treatment of caregivers of patients with schizophrenia may be associated with a higher risk of poor compliance compared to caregivers with positive beliefs about treatment.
The primary purpose is to explore the correlation between caregiver beliefs about treatment and patient compliance, taking into account the level of caregiver-patient link.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Impact of Caregiver Beliefs on Adherence to Antipsychotic Medications in Patients With Schizophrenia|
|Actual Study Start Date :||March 20, 2018|
|Estimated Primary Completion Date :||March 2, 2019|
|Estimated Study Completion Date :||March 30, 2019|
Patients and caregivers
Patients suffering from schizophrenia accompanied by their caregiver
- Assessment of the correlation between caregiver beliefs about treatment and patient compliance [ Time Frame: At day 1 ]The caregiver beliefs are evaluated by the Beliefs about Medicines Questionnaire, the patient compliance is evaluated by the investigator with Behaviourally Anchored Rating Scales and by the patient him-self with Morisky Medication Adherence Scale, and the level of caregiver-patient link is evaluated with Involvement Evaluation Questionnaire.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03471013
|Contact: Patrick LACARINfirstname.lastname@example.org|
|Clermont-Ferrand, France, 63003|
|Contact: Patrick LACARIN 0473751195 email@example.com|
|Principal Investigator: Ludovic SAMALIN|
|Sub-Investigator: Isabelle JALENQUES|
|Principal Investigator:||Ludovic SAMALIN||University Hospital, Clermont-Ferrand|